Xenetic Biosciences, Inc.

NasdaqCM:XBIO Stock Report

Market Cap: US$6.6m

Xenetic Biosciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jim Parslow

Chief executive officer

US$433.7k

Total compensation

CEO salary percentage75.9%
CEO tenure7.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure5.4yrs

Recent management updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

CEO Compensation Analysis

How has Jim Parslow's remuneration changed compared to Xenetic Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$5m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$434kUS$329k

-US$4m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$6m

Dec 31 2022US$474kUS$329k

-US$7m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$521kUS$299k

-US$6m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$359kUS$285k

-US$11m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$388kUS$265k

-US$18m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$288kUS$265k

-US$7m

Compensation vs Market: Jim's total compensation ($USD433.73K) is below average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Parslow (59 yo)

7.8yrs

Tenure

US$433,732

Compensation

Mr. James F. Parslow, also known as Jim, has been Chief Financial Officer at Xenetic Biosciences, Inc. since April 03, 2017 and serves as its Chief Operating Officer and Corporate Secretary and serves as i...

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Eisenberg
President & Director8.5yrsUS$563.49k0.027%
$ 1.8k
Moshe Mizrahy
Independent Non Executive Director1.1yrsUS$12.33k0%
$ 0
Roger Kornberg
Independent Director8.9yrsUS$57.54k0%
$ 0
Firdaus Dastoor
Independent Director11yrsUS$57.54k0%
$ 0
Dmitry Genkin
Non-Executive Director1.1yrsno data4.44%
$ 291.0k
Guenther Koehne
Member of Scientific Advisory Board5.7yrsno datano data
Matthew Frigault
Member of Scientific Advisory Board6yrsno datano data
Alexey Vinogradov
Independent Director5.5yrsUS$57.54kno data
Grigory Borisenko
Independent Non-Executive Director5.3yrsUS$57.54k0%
$ 0
Maksim Mamonkin
Member of Scientific Advisory Board4.9yrsno datano data
Allan Tsung
Member of Scientific Advisory Board2.7yrsno datano data
Jonathan Spicer
Member of Scientific Advisory Board2.2yrsno datano data

5.4yrs

Average Tenure

58yo

Average Age

Experienced Board: XBIO's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 21:57
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xenetic Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Kevin DeGeeterLadenburg Thalmann & Company
Rahul JasujaNOBLE Capital Markets, Inc.